



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd/Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Mark Hackett**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 5th July 2021
Ein Cyf / Our Ref: 21-F-015

01639 648363

FOIA.Requests@wales.nhs.uk

[Redacted]

Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

[Redacted]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 9th June 2021. Your request sought information relating to cancer treatment.

Please note that we have provided the information for the period 01.02.21 to 30.04.21.

1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

- Atezolizumab – 7
- Carboplatin with Gemcitabine - 5
- Carboplatin single or in any other combination - 0
- Cisplatin with Gemcitabine - <5*
- Cisplatin single or in any other combination - 0
- Nivolumab - 0
- Pembrolizumab - 0
- Any other regimen including Paclitaxel - 0
- Any other chemotherapy regimen - 0
- Other active systemic anti-cancer therapy [please state] - 0
- Palliative care only – 0 as first definitive treatment

2. Does your health board participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

No



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib - <5*
- Alectinib - <5*
- Atezolizumab monotherapy - <5*
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel - 0
- Bevacizumab - 0
- Brigatinib - 0
- Ceritinib - 0
- Crizotinib - <5*
- Dacomitinib - 0
- Dabrafenib with Trametinib - 0
- Docetaxel - 0
- Durvalumab - <5*
- Erlotinib - 0
- Gefitinib - <5*
- Gemcitabine - 0
- Nintedanib with Docetaxel - 0
- Nivolumab - 0
- Osimertinib - <5*
- Paclitaxel - 0
- Pembrolizumab monotherapy - 44
- Pembrolizumab chemo in combination - 13
- Pemetrexed with Carboplatin - 9
- Pemetrexed with Cisplatin - <5*
- Vinorelbine and cisplatin/carboplatin - <5*
- Any other active systemic anti-cancer therapy - 5
- Palliative care only – 15 as first definitive treatment

4. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?

Yes, please see details below

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer

No patients recruited.

A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

No patients recruited.

A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib



vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer
No patients recruited.

*Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



On behalf of

Pam Wenger

Director of Corporate Governance

